Hexavalent Pediatric Vaccine
Primary and booster vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenzae type b (Hib)
ApprovedActive
Key Facts
Indication
Primary and booster vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenzae type b (Hib)
Phase
Approved
Status
Active
Company
About MCM Vaccines
MCM Vaccine is a specialized joint venture between Sanofi and MSD, established to co-develop and commercialize a single hexavalent pediatric vaccine. The company leverages over 35 years of collaboration between its parent organizations, combining their proven antigens and extensive experience in vaccine development and manufacturing. Its sole product is a marketed vaccine indicated for primary and booster immunization, positioning the entity as a commercial-stage, single-asset company operating within a well-defined global partnership structure.
View full company profile